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Abstract
Background: Despite salvage radiation therapy (SRT) for recurrent prostate cancer (PCa) after
radical prostatectomy (RP), some patients still progress to metastases. Identifying these men
would allow them to undergo systemic therapy including testing novel therapies to reduce
metastases risk.
Objective: To test whether the genomic classiﬁer (GC) predicts development of metastatic
disease.
Design, setting, and participants: Retrospective multi-center and multi-ethnic cohort study
from two academic centers and one Veterans Affairs Medical Center in the United States
involving 170 men receiving SRT for recurrent PCa post-RP.
Outcome measurements and statistical analysis: Time from SRT to development of metastatic
disease tested using Cox regression, survival c-index, and decision curve analysis. Performance
of GC was compared to the Cancer of the Prostate Risk Assessment Score and Briganti risk
e metrics.
s: With amedian 5.7 yr follow-up after SRT, 20 patients (12%) developed
ariable analysis, for each 0.1 unit increase in GC (scaled from 0 to 1), theSalvage radiation therapy
Prognosis
models based on thes
Results and limitation
metastases. On multivMetastasis tasis was 1.58 (95% conﬁdence interval 1.16–2.17; p = 0.002). Adjusting
on therapy did not materially change the results. The c-index for GC was
nterval 0.73–0.88) versus 0.63–0.65 for published clinico-pathologic risk
ulative incidence of metastasis post-SRT in patients with low, interme-hazard ratio for metas
for androgen deprivati
0.85 (95% conﬁdence i
models. The 5-yr cum
diate, and high GC scores was 2.7%, 8.4%, and 33.1%, respectively (p < 0.001).
Conclusions: While validation in larger, prospectively collected cohorts is required, these data
suggest GC is a strong predictor of metastases amongmen receiving SRT for recurrent PCa post-
RP, accurately identifying men who are excellent candidates for systemic therapy due to their
very high-risk of metastases.
Patient summary: Genomic classiﬁer and two clinico-pathologic risk models were evaluated
on their ability to predict metastases among men receiving salvage radiation therapy for
recurrent prostate cancer. Genomic classiﬁer was able to identify candidates for further
therapies due to their very high-risk of metastases.
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Our ability to predict outcomes following salvage radiation
(SRT) for recurrent disease after radical prostatectomy (RP)
is poor. A prior study evaluated 1540 men treated with SRT
at multiple academic centers [1]. The best nomogram
predicted 6-yr prostate specific antigen (PSA) control with
69% accuracy. This compares poorly to other prostate cancer
(PCa) nomograms, which predict PCa death (a more
definitive endpoint) with 80% accuracy or higher at
diagnosis [2], post-RP [1,3], or at initial rising PSA post-
RP [4]. While intermediate endpoints (eg, rising PSA) are
important, assessment of risk factors for hard endpoints
such as metastasis are needed.
Advancements in genetics and high throughput ‘‘omics’’
coupled with a robust biomarker discovery program have
resulted in several commercially available tissue-based
molecular markers for PCa prognosis [5]. While these
markers have been evaluated in multiple populations, only
one has been examined on patients receiving radiation as
primary curative therapy [6] and none in men all receiving
SRT. Based upon performance in other populations, a
promising test is the Decipher genomic classifier (GC)
[7–9]. Unlike other tests that examined a limited number of
genes in their discovery [5], GC examined the whole tumor
gene expression profile. Thus, GC has the theoretical
advantage of capturing the entire tumor biology in one
signature. GC was developed among men undergoing RP at
the Mayo Clinic to predict metastases using a nested case-
control study design [7]. It has subsequently been evaluated
in multiple independent populations receiving varying
degrees of postoperative radiation [8,10,11], but never in
men who all received SRT. Importantly, these prior studies
all included men who received adjuvant radiation, some of
whom were cured with surgery alone. As such, it is
impossible to assess whether GC predicted response to
radiation or the likelihood of the surgery being curative,
which invariably would also relate to metastases risk.
Therefore, it is crucial to assess the ability of GC to identify
metastases risk in a more homogenous group of men who
all recurred and all received SRT to address whether GC
predicts outcomes after SRT.
To test whether GC predicts metastases after SRT, we
performed a multi-center study of men undergoing SRT
post-RP. Our population included men from two tertiary-
care referral centers and a Veterans Affairs (VA) hospital,
which contained nearly 50% African-American men. Impor-
tantly, no man in this study cohort was included in the GC
development. Thus, this study is an independent evaluation
of GC’s ability to predict metastases inmen undergoing SRT.
We hypothesized GC would predict metastases with high
accuracy, especially compared with standard clinico-
pathologic variables and two clinico-pathologic risk mod-
els: the Cancer of the Prostate Risk Assessment Post-
Surgical (CAPRA-S) model [12] and the Briganti risk model
[13], which was developed for predicting biochemical
recurrence following early SRT. Neither of these clinico-
pathologic risk models were initially designed to predict
metastasis. The Briganti model, however, represents arecent and relevant risk model for post-SRT patients while
CAPRA-S has been externally validated on a European
cohort to predict metastasis [14].
2. Materials and methods
2.1. Study cohort
A total of 170 RP patients who received postoperative SRT without prior
neoadjuvant or adjuvant therapy andwithout lymph node invasionwere
included. Lymph node invasion was deﬁned by the presence of at least
one node with a tumor. Seventy prostatectomy patients treated at
Durham VA between 1991 and 2010 with postoperative SRT were
obtained for analysis (Supplementary Fig. 1). Patients analyzed from
Thomas Jefferson University (n = 61; yr of RP 1991–2009) and Mayo
Clinic (n = 39; yr of RP 2000–2006) were obtained from a prior validation
study wherein GC had been performed using RP tumor tissue testing GC
for predicting metastases in men undergoing postoperative radiation
(adjuvant and salvage) [11]. Of the 188 patients in this prior study, only
100 received radiation with PSA > 0.2 ng/ml (ie, SRT), and were thus
included in the current study. Importantly, no patient in the current
study was included in the GC development [7,11]. Radiation therapy
regimens were as previously described where patients were treated to a
median dose of 66.6 Gy [11,15]. At all three institutions, only the
prostatic fossa is typically radiated for node negative patients. The
primary endpoint for the current study was metastasis (regional or
distant) detected using computed tomography and/or a bone scan. SRT
was deﬁned as radiation for PSA > 0.2 ng/ml or by radiation following
salvage androgen deprivation therapy (ADT). Concurrent ADT with SRT
was deﬁned as ADT administered within 3 mo of SRT [16–18]. ADT was
delivered at the discretion of the providing physician at each institution
with a median administration time of 12 mo post-RP. The study met the
REporting [4_TD$DIFF]recommendations for [5_TD$DIFF]tumor MARKer [6_TD$DIFF]prognostic [7_TD$DIFF]studies
criteria for evaluation of prognostic biomarkers [19]. The Institutional
Review Boards at Durham VA, Thomas Jefferson University, and Mayo
Clinic approved this study.
2.2. Tumor tissue sampling, RNA extraction, and testing
RP tumor specimens from Durham VA patients were selected after
restaging and regrading from the original hematoxylin and eosin slides.
Formalin-ﬁxed parafﬁn embedded tumor blocks with the highest
Gleason grade, and if present, extraprostatic extension or seminal
vesicle invasion were selected. Using a hematoxylin and eosin slide
freshly prepared from the formalin-ﬁxed parafﬁn embedded block, the
target region of tumor was selected to additionally have >80% tumor by
area to minimize presence of benign glands. The tumor was sampled
using a single 1.0-mm diameter disposable biopsy punch tool (Miltex,
York, PA, USA). RNA extraction, Affymetrix Human Exon 1.0 ST
oligonucleotide microarray (Affymetrix, Santa Clara, CA, USA) data
generation and preprocessing were as previously described [11]. The
approach for tissue selection and analysis was identical at the other sites,
as we have previously described [11].
2.3. Calculation of GC, clinico-pathologic risk models, and
combined models
GC is a locked risk model developed on a nested case-control data set
consisting of 545 patients from theMayo Clinic [7] which is independent
of the cohorts involved in the current study and thus there are no
overlapping patients. The expression values for the 22 prespeciﬁed
biomarkers constituting GC were extracted from the normalized data
matrix and entered into the random forest algorithm that was locked
[(Fig._1)TD$FIG]
Fig. 1 – Distribution of the study cohort by (A) Cancer of the Prostate
Risk Assessment Score, (B) Briganti (categorized by tertiles), and (C)
genomic classifier risk scores.
CAPRA-S = Cancer of the Prostate Risk Assessment Score; GC = genomic
classifier.
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[7]. Thus, each patient received only a single GC score. The GC read-out is
a continuous score between 0 and 1, with higher scores indicating
greater metastatic potential [7,8]. Previously established and locked cut-
points of 0.45 and 0.60 were used to categorize patients into low-,
intermediate-, and high-risk groups. These cut-points were selected by
optimizing the hazard ratio (HR) between both the intermediate- andhigh-risk categories versus the low-risk category using an independent
data set [10,20].
CAPRA-S scores [12] and Briganti scoreswere as previously described
[13]. The models in which GC was combined with either clinico-
pathologic variables or a clinico-pathologic risk model were generated
by internally ﬁtting a Cox model on the combined variables of interest.
2.4. Statistical analyses
In time-to-event analyses, event times were deﬁned as time from SRT
completion to metastases or date of last follow-up if no metastases.
The prognostic accuracy of CAPRA-S, Briganti, GC, and the combined
models was established based on time-dependent receiver operating
characteristic curves (survival c-index) [21]. Conﬁdence intervals (CIs)
for time-dependent c-indices were computed via bootstrap resampling.
Cumulative incidence curves of metastasis risk were constructed using
Fine-Gray competing risks analysis with death as a competing risk. To
address issues potentially arising due to a few events [8_TD$DIFF], penalized
likelihood Cox regression methods (least absolute shrinkage and
selection operator [LASSO] and Firth) were used for identifying the
most prognostic risk factors ensuring robustness of the analyses while
avoiding overestimation of risk factors [22]. As the penalty parameter, l,
in a LASSO regression tends to 0, more variables begin to have a nonzero
HR in a multivariable model. The order in which variables appear
indicates their order of importance in predicting metastasis. An
extension of decision curve analysis to survival data was used to
determine the net beneﬁt from the use of GC, CAPRA-S, and Briganti risk
models [23]. Survival c-indices were considered statistically signiﬁcant if
the lower bound of the 95% exceeded 0.50. The signiﬁcance level was
0.05 for all tests and analyses were performed in R v3.0.
3. Results
3.1. Patient characteristics
Our cohort was 32% African-American men and 68%
Caucasian-American. Consistent with a high-risk cohort
who all failed prostatectomy, 53% had extraprostatic
extension, 27%seminalvesicle invasion, and81%hadpositive
margins (Table 1). Eighteenpercent had a pathologicGleason
score  8. Median PSA prior to SRT was 0.6 ng/ml (range,
0.1–39; interquartile range, 0.4–1.7). Median time from
prostatectomy to SRTwas 12mo (range, 1–160; interquartile
range, 5–31). Nineteen percent received concurrent (within
3 mo of SRT) ADT with radiation and 18% received
nonconcurrent ADT (ie, >3 mo of SRT delivery). Median
follow-up post-RP and post-SRT among patients who did not
developmetastases or die was 7.4 yr and 5.7 yr, respectively.
During follow-up, 20 (12%) patients developed metastases.
Complete clinical data to calculate CAPRA-S and Briganti risk
models was available for 163 patients with 18 metastases.
CAPRA-S categorized 9.2% of these patients as low-riskwhile
41.8% were deemed low-risk by GC (Fig. 1).
3.2. GC as a predictor of metastases
Univariable analysis demonstrated that GC, pathologic
Gleason score  4+3, extraprostatic extension, and pre-
SRT PSA all significantly predicted post-SRT metastasis
(Table 2). GC remained an independent predictor after
adjusting for other clinical variables including concurrent
Table 1 – Demographic and clinical characteristics of eligible
patients.
Variables Study Cohort
No. patients (%) 170 (100)
Patient age, yr
Median (range) 61 (39, 75)
IQR (Q1, Q3) 56–66
Race, n (%)
African-American 54 (31.8)
Caucasian 115 (67.6)
Other 1 (0.6)
Preoperative PSA (ng/ml)
Median (range) 8.3 (0.4, 80.4)
IQR (Q1, Q3) 5.5–13.5
Pathologic Gleason score, n (%)
6 25 (14.7)
7 (3 + 4) 72 (42.4)
7 (4 + 3) 42 (24.7)
8 30 (17.6)
Unknown 1 (0.6)
Extraprostatic extension, n (%)
89 (52.7)
Seminal vesicle invasion, n (%)
45 (26.6)
Positive surgical margins, n (%)
137 (80.6)
Pre-SRT PSA (ng/ml)
Median (range) 0.6 (0.1, 39.0)
IQR (Q1, Q3) 0.4–1.7
Time from RP to SRT, mo
Median (range) 12.4 (1.3, 159.7)
IQR (Q1, Q3) 5.0–31.0
Concurrent ADT, n (%)
33 (19.4)
ADT administered at any time, n (%)
63 (37.1)
ADT= androgen deprivation therapy, IQR= interquartile range; PSA= prostate
speciﬁc antigen; RP= radical prostatectomy; RT= radiation treatment.
Table 2 – Cox univariable and multivariable analysis of clinico-patholo
Assessment Post-Surgical, and Briganti risk models for prediction of m
Variables HR (95% CI
Model I Patient age, yr 1.00 (0.93 -1.0
Log2 Preoperative PSA 1.22 (0.76 -1.9
Pathologic Gleason Score 3+4 Ref
Pathologic Gleason Score 4+3 3.45 (1.37 -9.5
Extraprostatic Extension 3.16 (1.18 -10
Seminal Vesicle Invasion 1.80 (0.68 -4.5
Positive Surgical Margins 0.50 (0.19 -1.4
Time from RP to SRT, months 0.98 (0.94 -1.0
Log2 Pre-SRT PSA 1.08 (1.03 -1.1
ADT 4.28 (1.66 -12
GCa 1.66 (1.25 -2.2
Model II CAPRA-Sb 1.20 (0.99 -1.4
GCb 1.66 (1.25 -2.2
Model III Brigantic 1.28 (1.00 -1.6
GCa 1.66 (1.25 -2.2
CI = conﬁdence interval; MVA = multivariable analysis; UVA, univariable analysi
a Genomic classiﬁer hazard ratios reported per 0.1 unit increase.
b Cancer of the Prostate Risk Assessment Post-Surgical hazard ratios reported pe
c Briganti hazard ratios reported per 25 unit increase.
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the risk of metastasis by 1.58 (95% CI 1.16–2.17; p = 0.002).
On multivariable analysis (MVA) adjusting for any ADT,
whether concurrent or otherwise, GC remained significant-
ly predictive of metastases (HR 1.56; p = 0.003; Supple-
mentary Table 1). The estimates of the HRs from a LASSO
Cox regression captures the importance of GC in predicting
metastasis as it was the first variable to enter the penalized
model (Fig. 2A), corroborating results from the MVA. The
final and least important variable to enter the model was
age at RP. Further, the addition of GC to any individual
clinico-pathologic variable or risk model significantly
improved their ability to discriminate risk (Fig. 2B). Finally,
the 5-yr cumulative incidence of metastasis post-SRT in
patients with low, intermediate, and high GC scores using
the previously locked cut-points of 0.45 and 0.60 was 2.7%,
8.4%, and 33.1%, respectively (p < 0.001; Fig. 3C).
3.3. Comparison of models to predict metastases
The survival c-index for GC (0.85; 95% CI 0.73–0.88) at 5 yr
post-SRT was substantially higher than for CAPRA-S (0.63;
95% CI 0.49–0.78) or Briganti (0.65; 95% CI 0.54–0.81;
Fig. 2C). The sensitivity and specificity for GC (to predict
metastasis at 5 yr post-SRT) was 94% and 54% using the
0.45 cut-off compared with 67% and 86% using the 0.60 cut-
off (Supplementary Fig. 3). While both Briganti and CAPRA-
S models significantly predicted metastases on univariable
analysis, neither was significantly correlated with metasta-
ses when modeled with GC on MVA (Table 2). Cumulative
incidence plots for metastasis by risk-category showed that
only GC significantly stratified risk (Fig. 3A–C). Consistent
with the better survival c-index, decision curve analysisgic variables, genomic classifier, Cancer of the Prostate Risk
etastasis.
UVA MVA
) p-value HR (95% CI) p-value
7) 0.992 0.99 (0.91 -1.07) 0.757
6) 0.417 1.28 (0.79 -2.11) 0.315
1.000 Ref 1.000
7) 0.008 1.46 (0.47 -4.76) 0.513
.34) 0.021 1.34 (0.38 -5.32) 0.655
0) 0.225 0.68 (0.21 -1.99) 0.483
9) 0.197 0.59 (0.21 -1.82) 0.335
0) 0.105 0.99 (0.95 -1.02) 0.397
1) 0.004 1.14 (0.88 -1.48) 0.327
.66) 0.002 2.74 (0.99 -8.54) 0.051
0) <0.001 1.56 (1.14 -2.12) 0.003
6) 0.068 1.12 (0.92 -1.37) 0.241
0) <0.001 1.63 (1.22 -2.18) <0.001
5) 0.022 1.14 (0.90 -1.45) 0.244
0) <0.001 1.62 (1.21 -2.18) <0.001
s.
r 1 unit increase.
[(Fig._2)TD$FIG]
Fig. 2 – (A) Least absolute shrinkage and selection operator coefficient path demonstrating the importance of genomic classifier (GC) and clinico-
pathologic variables in the prediction of metastasis. The optimal penalty parameter indicated by a vertical dashed line was found using 5-fold cross-
validation. (B) Survival c-indices for prediction of metastasis at 5 yr post-salvage radiation therapy (SRT) of clinico-pathologic variables, GC, and
combined GC plus clinico-pathologic models evaluated on individual data sets dependent upon the completeness of the clinico-pathologic variable of
interest. Error bars indicate the 95% confidence interval. (C) Survival c-indices at 5 yr post-SRT for GC, Cancer of the Prostate Risk Assessment Score,
and Briganti risk models for prediction of metastasis, and (D) decision curve analysis comparing net benefit at 5 yr post-SRT of GC, Cancer of the
Prostate Risk Assessment Score, and Briganti risk models across various threshold probabilities for prediction of metastasis.
ADT = androgen deprivation therapy; CAPRA-S = Cancer of the Prostate Risk Assessment Score; CI = confidence interval; EPE = extraprostatic extension;
GC = genomic classifier [2_TD$DIFF]; pPSA = preoperative prostate specific antigen; SRT = salvage radiation therapy; SVI = seminal vesicle invasion; RT = radiation
therapy.
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examined clinico-pathologic models (Fig. 2D) across a wide
range of decision threshold probabilities (0–25% metasta-
sis risk).
3.4. Impact of concurrent ADT on GC’s predictive ability
Percentages of patients in low-, intermediate-, and high-risk
GC groups who received concurrent ADT were 17.4%, 20.8%,
and 22.6%, respectively. A subset analysis to evaluate the
effect of concurrent ADT on GC risk group outcomes was
performed (Fig. 3D). Removing patients that received
concurrent ADT with SRT, who tended to be higher-risk,resulted in an overall decreasedmetastasis risk, although GC
remained strongly predictive of metastases post-SRT with
5-yr cumulative incidences for low, intermediate, and high
scores of 1.5%, 10.8%, and 28.8%, respectively (p = 0.009).
3.5. GC can reclassify men assigned to risk groups by CAPRA-S
or Briganti
Figure 1 shows thedistributionsofCAPRA-S, Briganti, andGC
scores. Using CAPRA-S, most patients were categorized as
intermediate- (55%) or high-risk (36%) for disease progres-
sion (Fig. 1A). As Briganti risk model does not specify risk
groups, convenience cut-points were used to approximate
[(Fig._3)TD$FIG]
Fig. 3 – Cumulative incidence curves of metastasis in which patients are stratified by (A) Cancer of the Prostate Risk Assessment Score risk categories,
(B) tertiles of Briganti risk scores, (C) genomic classifier risk categories, and (D) genomic classifier risk categories after excluding those patients whom
received concurrent androgen deprivation therapy.
CAPRA-S = Cancer of the Prostate Risk Assessment Score; GC = genomic classifier; SRT = salvage radiation therapy.
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GC tertiles for reclassification analysis. Using Briganti, the
distribution of patients grouped approximately by tertiles
was 27%, 43%, and 30% for low-, intermediate-, and high-risk
respectively (Fig. 1B). Reclassification analysis shows that
31 (39%) patients in the upper two tertiles of risk by Brigantiwere ‘down-graded’ to the first tertile by GC and notably
30 (97%) of these patients remained metastasis-free during
follow-up (Supplementary Table 2). With regards to CAPRA-
S,73(49%)patientswhowerecategorizedas intermediate-or
high-risk were reclassified as GC low-risk of which 70 (96%)
remained metastasis-free during follow-up.
E U RO P E AN URO LOGY 7 0 ( 2 0 1 6 ) 5 8 8 – 5 9 65943.6. Subset analysis of men receiving early SRT
As Briganti was developed for patients receiving early SRT
(pre-SRT PSA  0.5 ng/ml), we performed a secondary
analysis to calculate the c-index for this subset (n = 78).
Within this subset, only GC had a significant c-index of
0.79 (95% CI 0.72–0.85; Supplementary Fig. 2A) with neither
Briganti (c-index 0.44; 95% CI 0.34–0.78) nor CAPRA-S
(c-index 0.68; 95% CI 0.46–0.82) performing well. Similar
results were obtained in another secondary analysis using
PSA  1.0 ng/ml definition for early SRT (Supplementary
Fig. 2B).
4. Discussion
Treating patients with biochemical recurrence post-RP is
challenging. Several studies found SRT may be a second
chance of cure, especially in individuals without distant
metastasis [1,24–26]. However, as frequently observed in
medicine, a one-size-fits-all strategy is not necessarily
optimal. Indeed, while SRT can achieve long-term cancer
control in some patients, the response might be poor in
others. In this context, the ability to predict long-term cancer
control in these individuals is of outmost importance, as it
allows for an informed counseling of patients, a more
individualized follow-up scheme, and potentially more
effective treatment strategies.While somepredictionmodels
are available for these patients [1,13], their performance is
suboptimal. To address this limitation, we tested the
performance characteristics of the previously established
and lockedGC in predictingmetastasis after SRT inmenwith
recurrent disease post-RP.We relied on amulti-institutional,
multi-ethnic cohort, of which none were included in the GC
development, to maximize generalizability of our findings.
Our study has several important findings. Firstly, onMVA,
GC was an independent predictor of metastasis in patients
treated with SRT post-RP. Each 0.1-unit increase in GC was
associated with a 62% increase inmetastasis risk. Indeed, GC
separated a group with a 5-yr cumulative metastasis
incidence of 2.7% versus 33.1%. This indicates that GC is able
to correctly capture and categorize tumor aggressiveness.
Secondly, while the number of events was modest, we
exploredhowGCaffected the predictive ability of tools based
on clinical tumor characteristics (eg, CAPRA-S and Briganti)
and found when GC was added to the multivariable models,
these toolswerenot significantly linkedwithmetastases risk.
Moreover, when GC was modeled with individual clinico-
pathologic variables, only a minor improvement in discrimi-
nation performance was observed versus GC alone. This
suggests the examined genomic biomarker signature (GC)
explains all the variability captured by routinely available
clinical tumor characteristics. Thirdly, GC had the most
favorable discrimination accuracy versus CAPRA-S and
Briganti risk models, highlighting that this genomic bio-
marker captures variation in tumor behavior beyond the
ability of conventional clinical models.
To put these findings in clinical terms, we tested GC’s
ability to reclassifymen assigned to risk-groups by CAPRA-S
and Briganti risk models with the caveat that neither ofthese clinico-pathologic risk models were initially designed
to predictmetastasis. Almost 40–50% of patients classified as
intermediate- or high-risk by CAPRA-S and/or the Briganti
model were reclassified to low-risk by GC. Nearly all of these
patients (96–97%) remained metastasis free during follow-
up. This implies GC may optimize the prediction in a large
proportion of patients that would otherwise be classified
incorrectly as intermediate- or high-risk.
Our findingswereconfirmed,when, in secondaryanalysis,
we limited our inquiry to patients treated with SRT alone
(ie,without concurrentADT), or topatients treatedwithearly
SRT. Taken together, these observations imply GC has
important clinical implications and incorporating GC in
clinical practice can greatly improve our ability to predict
outcomes of patients with recurrent PCa undergoing SRT.
Given GC’s accuracy to predict metastases risk, the next
step is to better understand GC’s clinical utility. Despite
absence of completed randomized trials comparing adju-
vant to salvage radiation, most urologists in both Europe
and the United States [27] use SRT as a de facto standard of
care. Given the strong prognostication from GC, it appears
that patients with high GC should be considered for
systemic therapy in addition to SRT. For these men, the
recommendation is not to forego SRT, but rather that SRT
may not be enough and these patients are good candidates
for clinical trials or for additional therapies to combine with
SRT including docetaxel, which was recently shown to have
a survival benefit as adjuvant treatment for men with high-
risk PCa undergoing radiation plus ADT [28] as well as
several other settings [29,30].
Our study is not without limitations. Firstly, our results
were derived from retrospective observational data and,
therefore, the indication and selection of patients to undergo
SRTwas not standardized norwas the lymphnode dissection
standardized. This is evidenced by the variable time points at
which SRTwas received. Secondly, the number of eventswas
modest. Thirdly, not enough follow-up data was available to
address more definitive endpoints, such as cancer-specific
andoverallmortality. Larger sample sizeswith longer follow-
up are needed. Although most patients were imaged with
conventional computed tomography and bone scans, there
was a lack of standardization and absence of novel imaging
modalities (eg, sodium fluoride positron emission tomogra-
phy) to detectmetastases. Also, imaging intervalswere at the
discretion of the ordering physician. Finally, validation in
larger and more generalized and prospective cohorts is
necessary using PCa death as the endpoint.
5. Conclusions
Despite these limitations, our findings are particularly
intriguing and provide a unique, more individualized
approach to managing men receiving SRT post-RP. Indeed,
the GC biomarker provides accurate and comprehensive
insight regarding tumor aggressiveness in these individuals.
Specifically, this biomarker accurately down-staged almost
50% of patients predicted to harbor very aggressive tumors
by clinical features. Most importantly, it accurately
identifies a group of men with a 33% 5-yr risk of metastases
E U RO P E AN URO LOG Y 7 0 ( 2 0 1 6 ) 5 8 8 – 5 9 6 595despite SRT who may be excellent candidates for inclusion
into clinical trials for novel therapies due to their very high-
risk of metastases despite local salvage therapy.
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